Current Report Filing (8-k)
March 09 2022 - 7:51AM
Edgar (US Regulatory)
0000727346
false
0000727346
2022-03-04
2022-03-04
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported): March 4, 2022
SELECTIS
HEALTH, INC.
(Exact
Name of Registrant as Specified in its Charter)
Utah |
|
0-15415 |
|
87-0340206 |
(State
or other jurisdiction
of incorporation) |
|
Commission
File Number |
|
(I.R.S.
Employer
Identification number) |
8480
E. Orchard Road, Ste. 4900, Greenwood Village, CO |
|
80111 |
(Address
of principal executive offices) |
|
(Zip
Code) |
Registrant’s
telephone number, including area code: (720) 680-0808
(Former
name or former address, if changed since last report)
☐ |
Written
communications pursuant to Rule 425 under the Securities Act |
|
|
☐ |
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act |
|
|
☐ |
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act |
|
|
☐ |
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act |
Securities
registered pursuant to Section 12(b) of the Act:
Title
of each Class |
|
Trading
Symbol |
|
Name
of each exchange on which registered |
N/A |
|
N/A |
|
N/A |
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company ☒
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
ITEM
5.02 |
DEPARTURE
OF EXECUTIVE OFFICER AND DIRECTOR; APPOINTMENT OF EXECUTIVE OFFICER |
On
March 4, 2022, Mr. Brandon Thall tendered his resignation as Chief Financial Officer of Selectis Health, Inc. (the “Company”),
effective immediately. Christine Lucus, formerly serving as Controller, has been appointed interim CFO of the Company effective March
4, 2022.
Ms.
Lucus’ base salary will be $135,000 per year and she will be eligible to earn an additional $15,000 bonus if the Company’s
three 10-Q’s and 10-K are filed in a timely manner without extension.
Below
is the biographical information for Mrs. Lucus.
Christine
Lucus, age 32, joined the Company in April, 2021 as the Controller. Mrs. Lucus has spent her career in the pharmaceutical industry. Prior
to joining the Company, she was the Controller for NASDAQ listed Neubase Therapeutics, Inc. (formerly Ohr Pharmaceuticals) for seven
(7) years. She has focused on financial statements, 10Q and 10K SEC preparation and reporting, plan administration for the groups 401K,
FSA and health benefits and managing the balance sheet and income statement accounts by keeping reconciliations of each account and implementing
financial controls. Prior to Neubase Therapeutics, Inc. Ms. Lucus was
the Accounting and HR Manager for Drug Delivery, Inc.
Mrs.
Lucus has been an integral part of helping publicly held companies successfully raise capital in the public markets, most notably raising
$36 million in April 2020. She holds a Bachelor of Science Degree in Accounting from San Diego State University, where she served as
VP of Activities in Student Accountancy.
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned thereunto duly authorized.
|
Selectis
Health, Inc. (Registrant) |
|
|
Dated:
March 9, 2022 |
/s/
Lance Baller |
|
Lance
Baller, CEO |
Selectis Health (PK) (USOTC:GBCS)
Historical Stock Chart
From Jun 2024 to Jul 2024
Selectis Health (PK) (USOTC:GBCS)
Historical Stock Chart
From Jul 2023 to Jul 2024